TSP1 and MMP9 genetic variants in sporadic prostate cancer

Cancer Genetics and Cytogenetics

Volumn 172, Issue 1, 2007, Pages 38-44

  Sfar, Sana ^a   Saad, Hamadi ^b   Mosbah, Faouzi ^b   Gabbouj, Sallouha ^a   Chouchane, Lotfi ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b EPS Fattouma Bourguiba ^*  (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; THROMBOSPONDIN 1;

ADULT; AGED; AGGRESSIVENESS; ALLELE; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; THROMBOSPONDIN 1;

EID: 33845540635     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.07.014     Document Type: Article

References (41)

1. ACS. Cancer facts and figures (2004), American Cancer Society, Atlanta, GA
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
3. Mori A., Lehmann S., O'Kelly J., Kumagai T., Desmond J.C., Pervan M., McBride W.H., Kizaki M., and Koeffler H.P. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res 66 (2006) 3222-3229
4. Shields P.G., and Harris C.C. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18 (2000) 2309-2315
5. Carter B.S., Bova G.S., Beaty T.H., Steinberg G.D., Childs B., and Isaacs W.B. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150 (1993) 797-802
6. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 3 (1992) 65-71
7. Nicholson B., and Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91 (2004) 125-150
8. Brawer M.K., Deering R.E., Brown M., Preston S.D., and Bigler S.A. Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 73 (1994) 678-687
9. Ferrer F.A., Miller L.J., Andrawis R.I., Kurtzman S.H., Albertsen P.C., Laudone V.P., and Kreutzer D.L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157 (1997) 2329-2333
10. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
11. Folkman J. What is the role of thymidine phosphorylase in tumor angiogenesis?. J Natl Cancer Inst 88 (1996) 1091-1092
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
13. Iruela-Arispe M.L., Luque A., and Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 36 (2004) 1070-1078
14. Taraboletti G., Roberts D., Liotta L.A., and Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111 (1990) 765-772
15. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138 (1997) 707-717
16. Wang T.N., Qian X., and Granick M.S. Thrombospondin-1 (TSP1) promotes the invasive properties of human breast cancer. J Surg Res 63 (1996) 39-43
17. Zabrenetzky V., Harris C.C., Steeg P.S., and Roberts D.D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 59 (1994) 191-195
18. Vallbo C., and Damber J.E. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. Acta Oncol 44 (2005) 293-298
19. Jin R.J., Kwak C., and Lee S.G. The application of an antiangiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 7 (2000) 1537-1542
20. Topol E.J., McCarthy J., Gabriel S., Moliterno D.J., Rogers W.J., Newby L.K., Freedman M., Metivier J., Cannata R., O'Donnell C.J., Kottke-Marchant K., Murugesan G., Plow E.F., Stenina O., and Daley G.Q. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 104 (2001) 2641-2644
21. 2+ binding. J Biol Chem 279 (2004) 51915-51922
22. 2+-binding repeats. J Biol Chem 278 (2003) 8929-8934
23. Lawler J., Derick L.H., Connolly J.E., Chen J.H., and Chao F.C. The structure of human platelet thrombospondin. J Biol Chem 260 (1985) 3762-3772
24. Narizhneva N.V., Byers-Ward V.J., Quinn M.J., Zidar F.J., Plow E.F., Topol E.J., and Byzova T.V. Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J Biol Chem 279 (2004) 21651-21657
25. Lawler J., and Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36 (2004) 1038-1045
26. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., and Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 98 (2001) 12485-12490
27. Opdenakker G., Van den Steen P., and Dubois B. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69 (2001) 851-859
28. Zhang L., Shi J., Feng J., Klocker H., Lee C., and Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7 (2004) 327-332
29. Aalinkeel R., Nair M.P., Sufrin G., Mahajan S.D., Chadha K.C., Chawda R.P., and Schwartz S.A. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 64 (2004) 5311-5321
30. Zhang X.Y., Hong B.F., Chen G.F., Lu Y.L., and Zhong M. Significance of MMP2 and MMP9 expression in prostate cancer. [In Chinese; abstract in English]. Zhonghua Nan Ke Xue 11 (2005) 359-361 364
31. Bergers G., Brekken R., and McMahon G. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
32. Sheu B.C., Hsu S.M., Ho H.N., Lien H.C., Huang S.C., and Lin R.H. A novel role of metalloproteinase in cancer mediated immunosuppression. Cancer Res 61 (2001) 237-242
33. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., Arveiler D., Luc G., Cambien F., Hamsten A., Watkins H., and Henney A.M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999) 1788-1794
34. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
35. Zhou X., Huang J., Chen J., Zhao J., Ge D., Yang W., and Gu D. Genetic association analysis of myocardial infarction with thrombospondin-1 N700S variant in a Chinese population. Thromb Res 113 (2004) 181-186
36. Zwicker J.I., Peyvandi F., Palla R., Lombardi R., Canciani M.T., Cairo A., Ardissino D., Bernardinelli L., Bauer K.A., Lawler J., and Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood 108 (2006) 1280-1283
37. Matsumura S., Oue N., Nakayama H., Kitadai Y., Yoshida K., Yamaguchi Y., Imai K., Nakachi K., Matsusaki K., Chayama K., and Yasui W. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131 (2005) 19-25
38. Zhang X.M., Miao X.P., Xiong P., Yu C.Y., Tan W., Qu S.N., Sun T., Zhou Y.F., and Lin D.X. Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population. [In Chinese; abstract in English]. Ai Zheng 23 (2004) 1233-1237
39. Grieu F., Li W.Q., and Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88 (2004) 197-204
40. Wang Y., Fang S., Wei L., Wang R., Jin X., Wen D., Li Y., Guo W., Wang N., and Zhang J. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 49 (2005) 155-161
41. Awakura Y, Ito N, Nakamura E, Takahashi T, Kotani H, Mikami Y, Manabe T, Kamoto T, Habuchi T, Ogawa O. Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett 2006 Feb 6 [Epub ahead of print; doi:10.1016/j.canlet.2005.10.005].